Zydus Lifesciences Ltd.

₹1,145.7

-16.3 (-1.4%)

ZYDUSLIFE Share Price

Pharmaceuticals & Biotechnology

As on October 1, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 1,14,239 Cr

P/E Ratio22.87

Dividend Yield0.09 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,185.42	Bearish
10-DMA	1,176.08	Bearish
20-DMA	1,151.61	Bearish
50-DMA	1,141.19	Bullish
100-DMA	1,115.48	Bullish
200-DMA	1,011.13	Bullish

Historical Performance

1 Year

15.6%

3 Years

86.3%

5 Years

106.2%

10 Years

195.4%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	2,71,484	2,32,415	1,95,474	1,72,374	1,51,099
Total Expenditure	1,99,584	1,63,480	1,42,484	1,36,655	1,19,352
Other Income	17,946	4,596	3,694	4,746	3,907
Operating Profit	89,846	73,531	56,684	40,465	35,654
Interest	4,389	1,910	812	1,299	1,270
Depreciation	14,080	9,158	7,641	7,227	7,130
Profit Before Tax	66,211	60,267	48,089	25,897	28,381
Consolidated Net Profit	50,400	45,255	38,595	19,603	44,873
Adjusted EPS	50	45	38	19	44

Compounded Sales Growth

10 Years:23.6

5 Years:13.5

3 Years:9.5

TTM:3.2

Compounded Profit Growth

10 Years:21.1

5 Years:18.8

3 Years:20.8

TTM:2.2

Stock Price CAGR

10 Years:11.4

5 Years:15.6

3 Years:23.3

TTM:15.9

Return on Equity

10 Years:14.5

5 Years:43.8

3 Years:38.4

last year:50.1

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	1,006	1,006	1,006	1,012	1,024
Total Reserves	2,70,108	2,38,525	1,97,289	1,74,146	1,68,972
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	50,039	-5,421	1,931	-7,250	-1,936
Other Current Liabilities	76,204	25,243	16,776	17,985	19,675
Short Term Borrowings	44,016	31,695	7,686	10,810	33,141
Total Liabilities	5,02,980	3,48,579	2,76,366	2,44,940	2,66,996
Capital Work in Progress	11,657	13,179	11,115	11,302	6,610
Long Term Loans & Advances	7,766	4,001	3,445	3,587	3,693
Currents Investments	57,758	48,555	2,525	6,193	23,532
Short Term Loans and Advances	11,822	7,044	7,359	7,117	13,455
Total Current Assets	1,99,061	1,70,461	1,14,198	1,00,082	1,20,952
Total Assets	5,02,980	3,48,579	2,76,366	2,44,940	2,66,996
Adjusted Book Value	269	238	197	173	166

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 22.87, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a strong 3-year price CAGR of 23.3%, indicating sustained price appreciation.
The stock carries a low beta of 0.6, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹89846 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹271484 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1159263.4

No. of Shares: 1012 (Approx)

Performance:15.9%

159263.4

NIFTY Performance: -9.9%

1 day Top Gainers